STAAR Surgical Co. reported preliminary second-quarter net sales exceeding $90 million, more than double the $44.3 million from a year earlier. The stock traded lower Friday as Middle East geopolitical tensions weighed on investor sentiment despite the strong revenue growth.
STAAR Surgical Co. reported preliminary second-quarter net sales exceeding $90 million, more than double the $44.3 million from a year earlier. The stock traded lower Friday as Middle East geopolitical tensions weighed on investor sentiment despite the strong revenue growth.
STAAR Surgical's preliminary Q2 revenue more than doubled to over $90 million, yet shares fell Friday as Middle East geopolitical risks overshadowed the strongest sales growth in the company's history.
The company disclosed the preliminary figures in a press release, citing demand for its EVO Implantable Collamer Lens used in vision correction. STAAR did not provide full financial results or updated guidance for the remainder of the year.
The preliminary net sales of more than $90 million compare with $44.3 million in the same period last year, representing year-over-year growth exceeding 100%. The company has not yet disclosed earnings per share or consensus comparisons.
The disconnect between strong fundamentals and negative price action suggests geopolitical risk is currently outweighing earnings momentum for the Monrovia, California-based medical device maker. Investors will watch for full Q2 results and any regional exposure details when the company reports complete earnings.
STAAR Surgical's EVO lens is one of the few FDA-approved implantable collamer lenses for vision correction, competing with laser-based procedures from Alcon Inc. and Johnson & Johnson Vision. The company has been expanding its global footprint, with international markets including the Middle East accounting for a growing share of revenue. In fiscal 2025, international sales represented roughly 60% of total revenue, according to company filings.
The stock's decline comes as broader market concerns about Middle East instability have weighed on companies with regional exposure. STAAR's preliminary results suggest demand for its vision correction products remains strong, but the path to realizing that growth in affected regions remains uncertain. The company's full Q2 report, expected in the coming weeks, will provide greater clarity on regional performance and margin trends.
This article is for informational purposes only and does not constitute investment advice.
